Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo vitamin settlement

This article was originally published in The Tan Sheet

Executive Summary

Private labeler will record $20.1 mil. pre-tax gain in fiscal fourth quarter ending June 30 stemming from settlements in vitamin price-fixing litigation. Settlement proceeds, which were received May 17, will boost net income by approximately $12.9 mil. Perrigo recorded $7.8 mil. pre-tax gain in Q3 following similar settlements (1"The Tan Sheet" Feb. 18, 2002, p. 14)...

You may also be interested in...



Perrigo vitamin settlement

Private labeler will record $7.8 mil. pre-tax gain in third quarter ending March 31 stemming from settlement with unidentified defendants in vitamin price-fixing litigation. "Effect on net income will be approximately $5 mil.," firm says in Feb. 1 SEC filing. Case against remaining price-fixing defendants is proceeding, notes Allegan, Mich.-based firm, which previously reported vitamin litigation settlement payments of $995,000 and $4.2 mil. for FY 2001 and 2000, respectively...

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS094101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel